

British Journal of Cancer (2013) 108, 1387 | doi: 10.1038/bjc.2012.528

## On the clinical relevance of circulating endothelial cells and platelets in prostate cancer

F Bertolini\*,1, Y Shaked<sup>2</sup> and P Mancuso<sup>1</sup>

<sup>1</sup>Laboratory of Hematology-Oncology, European Institute of Oncology, Milan, Italy and <sup>2</sup>Rappaport Faculty of Medicine, Department of Molecular Pharmacology, Technion-Israel Institute of Technology, Haifa, Israel

Sir

In their interesting study Wong et al (2012) report a preclinical and clinical correlation between the number of CD45 – CD31 + cells in the peripheral blood and the growth of prostate cancer. Using flow cytometry and microscopy, they suggest that the large majority of CD45 – CD31 + cells are more likely immature platelets and not circulating endothelial cells (CECs). Considering the wide antigenic overlap between CECs and platelets, and the possible aggregation/adhesion of platelets with CECs, we and others feel that in multiparametric flow cytometry the use of a cell viability stain and of a DNA-specific staining are necessary to discriminate DNA-containing CECs from DNA-free, CEC-derived macroparticles and platelets (Bertolini et al, 2006; Mancuso and Bertolini, 2010; Mund et al, 2012).

When Ning et al (2010) used a nucleic acid stain to enumerate CECs in prostate cancer patients receiving Bevacizumab, Docetaxel, Thalidomide and Predinisone, they reported a strong inverse correlation between changes in apoptotic CECs and PSA levels, suggesting that the drug combination may effectively inhibit tumour angiogenesis. Along this line, Strijbos et al (2010) used a nuclear stain to enumerate CECs in prostate cancer patients receiving Docetaxel. They reported that CECs' kinetics during treatment, alone or in combination with other biomarkers, predicted survival in this cancer population.

Data from Wong et al (2012) suggest that immature platelets deserve further clinical investigation as possible biomarkers of disease status in metastatic prostate cancer. One of the unique features of multiparametric flow cytometry is the possibility to enumerate in the same test-tube several different populations of cells, such as DNA-containing CECs, DNA-free, CEC-derived macroparticles and platelets. Several previous clinical studies

involving antiangiogenic therapeutics in cancer patients indicated that these different cell and platelet populations might serve as unique predictive and/or prognostic biomarkers. We, therefore, recommend investigating them all in parallel in one test-tube using multiparametric flow cytometry technique.

## **REFERENCES**

Bertolini F, Shaked Y, Mancuso P, Kerbel RS (2006) The multifaceted circulating endothelial cell in cancer: from promiscuity to surrogate marker and target identification. *Nat Reviews Cancer* **6**(11): 835–845.

Mancuso P, Bertolini F (2010) Circulating endothelial cells as biomarkers in clinical oncology. Microvascular Res 79(3): 224–228.

Mund JA, Estes ML, Yoder MC, Ingram Jr DA, Case J (2012) Flow cytometric identification and functional characterization of immature and mature circulating endothelial cells. *Arterioscler Thromb Vasc Biol* **32**(4): 1045–1053.

Ning YM, Gulley JL, Arlen PM, Woo S, Steinberg SM, Wright JJ, Parnes HL, Trepel JB, Lee MJ, Kim YS, Sun H, Madan RA, Latham L, Jones E, Chen CC, Figg WD, Dahut WL (2010) Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. *J Clin Oncol* 28(12): 2070–2076.

Strijbos MH, Gratama JW, Schmitz PI, Rao C, Onstenk W, Doyle GV, Miller MC, de Wit R, Terstappen LW, Sleijfer S (2010) Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel. *Eur J Cancer* **46**(11): 2027–2035.

Wong CKE, Namdarian B, Chua J, Chin X, Speirs R, Nguyen T, Fankhauser M, Pedersen J, Costello AJ, Corcoran NM, Hovens CM (2012) Levels of a subpopulation of platelets, but not circulating endothelial cells, predict early treatment failure in prostate cancer patients after prostatectomy. Br J Cancer 107(9): 1564–1573.

\*Correspondence: Dr F Bertolini; E-mail: francesco.bertolini@ieo.it

Published online 14 February 2013

© 2013 Cancer Research UK. All rights reserved 0007 - 0920/13